HK1252821A1 - 用於治療具有rtk突變細胞的患者的組合物和方法 - Google Patents
用於治療具有rtk突變細胞的患者的組合物和方法Info
- Publication number
- HK1252821A1 HK1252821A1 HK18112149.5A HK18112149A HK1252821A1 HK 1252821 A1 HK1252821 A1 HK 1252821A1 HK 18112149 A HK18112149 A HK 18112149A HK 1252821 A1 HK1252821 A1 HK 1252821A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- treating patients
- mutant cells
- rtk
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562168237P | 2015-05-29 | 2015-05-29 | |
US201662309900P | 2016-03-17 | 2016-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1252821A1 true HK1252821A1 (zh) | 2019-06-06 |
Family
ID=57441630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18112149.5A HK1252821A1 (zh) | 2015-05-29 | 2018-09-20 | 用於治療具有rtk突變細胞的患者的組合物和方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US20180177792A1 (zh) |
EP (1) | EP3303382A4 (zh) |
JP (2) | JP6929231B2 (zh) |
CN (1) | CN107849113B (zh) |
AU (1) | AU2016270321B2 (zh) |
CA (1) | CA2987281A1 (zh) |
HK (1) | HK1252821A1 (zh) |
MA (1) | MA43943A (zh) |
WO (1) | WO2016196141A1 (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS53350B (en) | 2008-09-22 | 2014-10-31 | Array Biopharma, Inc. | SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS |
KR101634833B1 (ko) | 2008-10-22 | 2016-06-29 | 어레이 바이오파마 인크. | TRK 키나아제 억제제로서 치환된 피라졸로[1,5a] 피리미딘 화합물 |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
EP2918588B1 (en) | 2010-05-20 | 2017-05-03 | Array Biopharma, Inc. | Macrocyclic compounds as TRK kinase inhibitors |
US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
DK3699181T3 (da) | 2014-11-16 | 2023-03-20 | Array Biopharma Inc | Krystallinsk form af (s)-n-(5-((r)-2-(2,5-difluorphenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidin-1-carboxamidhydrogensulfat |
CN107207471B (zh) | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
BR112018008357A2 (pt) | 2015-10-26 | 2018-11-27 | Array Biopharma Inc | mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas |
AU2016370846B2 (en) | 2015-12-18 | 2022-08-25 | Ignyta, Inc. | Combinations for the treatment of cancer |
TN2019000332A1 (en) | 2016-04-04 | 2021-05-07 | Loxo Oncology Inc | Methods of treating pediatric cancers |
US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
RU2751767C2 (ru) | 2016-04-04 | 2021-07-16 | Локсо Онколоджи, Инк. | Жидкие составы (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида |
LT3458456T (lt) | 2016-05-18 | 2021-02-25 | Loxo Oncology, Inc. | (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamido gavimas |
JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
JP7203083B2 (ja) | 2017-07-19 | 2023-01-12 | イグナイタ インコーポレイテッド | エントレクチニブを含む薬学的組成物 |
EP3697390A1 (en) | 2017-10-17 | 2020-08-26 | Ignyta, Inc. | Pharmaceutical compositions and dosage forms |
CA3089566A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
CN114615982A (zh) | 2019-08-12 | 2022-06-10 | 德西费拉制药有限责任公司 | 用于治疗胃肠道间质瘤的瑞普替尼 |
WO2021030405A1 (en) | 2019-08-12 | 2021-02-18 | Deciphera Pharmaceuticals, Llc | Ripretinib for treating gastrointestinal stromal tumors |
CN110643672A (zh) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途 |
LT4084778T (lt) | 2019-12-30 | 2024-01-25 | Deciphera Pharmaceuticals, Llc | Amorfinės kinazės inhibitoriaus vaistinės formos ir jų panaudojimo būdai |
CN115243681A (zh) | 2019-12-30 | 2022-10-25 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
WO2021178789A1 (en) * | 2020-03-06 | 2021-09-10 | Deciphera Pharmaceuticals, Llc | Methods of using rebastinib in the treatment of different cancerous disorders |
US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
CN116254253A (zh) * | 2022-11-11 | 2023-06-13 | 浙大宁波理工学院 | 一种通过dna合成改组组合突变获得的谷氨酸脱羧酶突变体及应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002275068A (ja) * | 2001-03-16 | 2002-09-25 | Kyowa Hakko Kogyo Co Ltd | アポトーシス誘導剤 |
AU2003271489B2 (en) * | 2003-10-24 | 2009-02-19 | Oncalis Ag | Method for the identification and/or validation of receptor tyrosine kinase inhibitors |
WO2006111035A1 (en) * | 2005-04-21 | 2006-10-26 | Oncalis Ag | Method for the identification of possibly harmful receptor tyrosine kinase (rtk) mutations and of inhibitors or medication directed against rtk mutantstitle |
CA2617898A1 (en) * | 2005-08-09 | 2007-02-15 | Martin Schuler | Staurosporine derivatives for treating non-small cell lung cancer |
SG177225A1 (en) * | 2006-12-01 | 2012-01-30 | Agency Science Tech & Res | Cancer-related protein kinases |
CA2693901C (en) * | 2007-07-20 | 2015-12-29 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
US20110229485A1 (en) | 2008-05-21 | 2011-09-22 | Centre National De La Recherche Scientfique (Cnrs) | Inhibition of the nt-3:trkc bound and its application to the treatment of cancer such as neuroblastoma |
KR101634833B1 (ko) * | 2008-10-22 | 2016-06-29 | 어레이 바이오파마 인크. | TRK 키나아제 억제제로서 치환된 피라졸로[1,5a] 피리미딘 화합물 |
US8383793B2 (en) * | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
CA2828219A1 (en) * | 2011-02-25 | 2012-08-30 | Irm Llc | Pyrazolo [1,5-a] pyridines as trk inhibitors |
CN102924479A (zh) * | 2011-08-09 | 2013-02-13 | 山东鲁北药业有限公司 | 一种星孢菌素类衍生物的半合成方法 |
-
2016
- 2016-05-25 EP EP16804039.2A patent/EP3303382A4/en active Pending
- 2016-05-25 CN CN201680040063.7A patent/CN107849113B/zh active Active
- 2016-05-25 US US15/577,729 patent/US20180177792A1/en not_active Abandoned
- 2016-05-25 JP JP2017560654A patent/JP6929231B2/ja active Active
- 2016-05-25 MA MA043943A patent/MA43943A/fr unknown
- 2016-05-25 AU AU2016270321A patent/AU2016270321B2/en not_active Withdrawn - After Issue
- 2016-05-25 WO PCT/US2016/034166 patent/WO2016196141A1/en active Application Filing
- 2016-05-25 CA CA2987281A patent/CA2987281A1/en not_active Abandoned
-
2018
- 2018-09-20 HK HK18112149.5A patent/HK1252821A1/zh unknown
-
2021
- 2021-06-01 JP JP2021092592A patent/JP7219791B2/ja active Active
- 2021-06-23 US US17/356,128 patent/US20210322439A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3303382A4 (en) | 2018-12-19 |
MA43943A (fr) | 2018-12-12 |
US20180177792A1 (en) | 2018-06-28 |
WO2016196141A1 (en) | 2016-12-08 |
JP6929231B2 (ja) | 2021-09-01 |
US20210322439A1 (en) | 2021-10-21 |
JP2021156893A (ja) | 2021-10-07 |
AU2016270321A1 (en) | 2017-12-14 |
JP7219791B2 (ja) | 2023-02-08 |
CA2987281A1 (en) | 2016-12-08 |
AU2016270321B2 (en) | 2020-09-10 |
CN107849113B (zh) | 2022-03-22 |
EP3303382A1 (en) | 2018-04-11 |
AU2016270321A2 (en) | 2018-01-04 |
CN107849113A (zh) | 2018-03-27 |
JP2018521973A (ja) | 2018-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1252821A1 (zh) | 用於治療具有rtk突變細胞的患者的組合物和方法 | |
HK1244826A1 (zh) | 用於過繼細胞治療的方法和組合物 | |
HK1243333A1 (zh) | 用於修飾的t細胞的方法和組合物 | |
HK1243640A1 (zh) | 用於治療潰瘍的方法和組合物 | |
IL246544A0 (en) | A compound for the treatment of patients with ros1 mutant cancer cells | |
HK1225654A1 (zh) | 用於治療老花眼的組合物及方法 | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
HK1245641A1 (zh) | 次氯酸製劑及治療皮膚病的方法 | |
HK1255101A1 (zh) | 用於得到調節性t細胞的方法及其用途 | |
HRP20190194T1 (hr) | 17a,21-diesteri korteksolona, namijenjeni liječenju tumora | |
HK1232152A1 (zh) | 用於治療異常細胞生長的方法和組合物 | |
EP3139928A4 (en) | Anordrin compositions and methods for treating diseases | |
IL246607A0 (en) | Improved cellular preparations and methods for cancer treatment | |
EP3110446A4 (en) | Methods and compositions for treating siglec-8 associated diseases | |
IL263218A (en) | Compounds and methods for microbiotic therapy | |
EP3145516A4 (en) | Methods and compositions for treating malignancies with dendritic cells | |
EP3226972A4 (en) | Methods and compositions for treating migraine and conditions associated with pain | |
EP3164132A4 (en) | Methods and compositions for treating diseases and conditions | |
EP3139744A4 (en) | Methods and compositions for treating and preventing tinnitus | |
HK1244782A1 (zh) | 用於治療疾病和病癥的組合物和方法 | |
GB201521083D0 (en) | Compositions for treatment and methods thereof | |
GB201511772D0 (en) | Improvements in the treatment of ash | |
SG10201400823PA (en) | Therapeutic methods and compositions for treating diabetes |